<DOC>
	<DOC>NCT02231736</DOC>
	<brief_summary>The purpose of the study is to determine whether glycemic control (HbA1c) is linked to chromosomal damage in type 2 Diabetes patients</brief_summary>
	<brief_title>Chromosomal Damage in Type 2 Diabetes Patients (MIKRODIAB)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Type 2 Diabetes (T2DM) Sex: female Age: &gt; 30years Medication: oral antidiabetics and/or Insulin therapy Constant nutritional behavior, constant physical activity, constant weight for the last 4 weeks Nonsmoking for at least 1 year Patients with type 1 DM Age: &lt; 30years Pregnant or lactating women Participation in another clinical trial Change of medication in regard to metabolic parameters within the last 4 weeks Significant cardiovascular damage with NYHA &gt; III Liver disease with threetimes higher transaminase values Chronic kidney disease with serum creatinine &gt; 2 mg/dl Dialysis HIV positive History of chronic alcohol abuse in the last two years History of cancer, stroke, organ transplantation Male</criteria>
	<gender>Female</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Type 2 Diabetes</keyword>
	<keyword>Chromosomal damage</keyword>
	<keyword>Micronuclei</keyword>
	<keyword>DNA damage</keyword>
	<keyword>HbA1c</keyword>
	<keyword>Comet Assay</keyword>
	<keyword>Glycemic control</keyword>
</DOC>